Novo Nordisk to Acquire Dicerna Pharmaceuticals (GalXC RNAi Platform)

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to €1.025 Billion

March 25, 2024

Biotechnology

Novo Nordisk agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, consisting of an upfront payment plus additional milestone payments tied to development and commercial progress. The deal is expected to strengthen Novo Nordisk’s cardiovascular pipeline, centered on Cardior’s lead candidate CDR132L in phase 2 heart failure trials.

Eli Lilly and Company to Acquire Orna Therapeutics in Up to $2.4 Billion Deal

February 9, 2026

Biotechnology

Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics in a deal valued at up to $2.4 billion. The acquisition is intended to expand Lilly’s capabilities in genetic medicine and in vivo cell engineering, particularly to advance in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle platform.

Danaher Acquires Aldevron for $9.6 Billion

June 17, 2021

Biotechnology

Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

October 10, 2025

Pharmaceuticals

Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.

Novo Nordisk Acquires Forma Therapeutics

September 1, 2022

Pharmaceuticals

Novo Nordisk will acquire Forma Therapeutics in a cash tender offer at $20 per share, valuing the deal at about $1.1 billion. The acquisition is intended to expand Novo Nordisk’s scientific and pipeline presence in sickle cell disease and other rare blood disorders, including Forma’s lead candidate etavopivat.